Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Filing today

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Nov 08, 2023 9:42am

101 Views

Post# 35723362

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Filing today

Problem is you can tell an equally sorry story on cash generation. For all the news Scarlett brings about Egrifta, some of it generated by the company, it doesn't look like they've convinced the clinical community that it's anything more than it was initially understood to be. The numbers on the drug suggest the drug profile hasn't changed all that much. So they bounce along with more or less similar Qs. Wino probably had it yesterday in saying controlling costs are their best options.

palinc2000 wrote:
Going into debt in the first place was and is the most stupidest move a small biotech can make!!
The second stupidest move they made was to repay the first debt by debt under the pretense of 'non dilutive financing"" just to please large shareholders believing that the lottery ticket bought 4 years before would be a winning ticket.... Not only did it prove to be very dilutive and a lot more dilutive than it could have been and turned out to be almost 100% destructive..
The focus needs to be on cash generation and getting rid of Marathon...I think that this is their plan but time will tell

THobsv wrote:
All of these comments are fair, they have lots of levers, they should hopefully have created reasonable adjusted EBITDA targets, etc. But we must remember this is a management team that raised equity at $1 to give them the cash they would have needed to satisfy the old cash requirements AFTER switching to an EBITDA target. They are not making smart or strategic decisions. We don't know what the targets are, anything is possible.

The most positive development to me, by far, is Soleus adding 9mm shares and tripling down on their investment. This is a tiny investment for them even after that add, but they could have just walked away. They also own a huge chunk of the company and can have more influence if they choose.

At this point we have to assume management will at best do minimal harm to the business, but shouldn't expect them to make any value add decisions and can't take anything for granted.